Observing MADD over time
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people with MADD to learn how the condition changes over time. It aims to improve understanding and future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Multiple Acyl-CoA Dehydrogenase Deficiency (MADD), confirmed by a doctor from the study
- You or your legal guardian can sign a consent form (and you agree if you are a child)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how medium-chain fatty acids (a type of fat found in coconut oil) affect metabolism in people with MCADD, a genetic condition that affects fat breakdown, compared to healthy people. The results may help guide dietary advice for those with MCADD.
This trial tests a medicine called sodium phenylbutyrate (ACER-001) to see if it helps people with MCADD, a genetic condition that affects how your body breaks down fats. If you have MCADD and the common gene change, you might be able to join.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study tracks people with fatty liver disease over several years to see how their health changes. By joining, you help researchers understand the long-term effects of different types of liver disease.
This study tracks how SSADH deficiency (a genetic condition) affects health over time. There is no new drug being tested; instead, researchers collect medical history and perform certain optional scans/tests that can help describe disease patterns and future treatment needs.
This study looks at how metabolism, infections, and the immune system work together in people with mitochondrial disease. It aims to learn more about the condition and may help guide future treatments.
Hear when a new Multiple Acyl-CoA Dehydrogenase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.